Digital RESI March Panel Line-up

2 Feb

By Love Chung, Investor Research Analyst, LSN

Love-headshot

The Redefining Early Stage Investment (RESI) conference series returns this March 14-16 in a fully virtual format. Through a carefully curated agenda including Innovator’s Pitch Challenges, educational workshops, panels, and more, entrepreneurs will be able to connect with investors and strategic partners who best match their product and stage of development. The panels will continue to feature investors, industry experts, and seasoned entrepreneurs providing valuable insight to our conference attendees.

Digital RESI March will be bringing on investor panels (featuring investors representing groups such as Angels, Corporate Venture Capital, Family Offices) that entail key topics of life science such as Therapeutics, Chronic Disease Management, Impact Investing, Health Systems, and more. Click here to see the agenda of the upcoming conference. To save $200 on Digital RESI, make sure to complete the early bird registration by February 10th!

Digital-RESI-March-Panel-Agenda

Digital RESI March 2023 Email Banner.(NEWtouse)

I Asked an AI Robot to Tell Me About Entrepreneurial Storytelling (I am not kidding)

2 Feb

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

I asked the Robot, Open AI, Chat GPT to write an article on why scientist entrepreneurs and fundraising CEOs need to get their stories straight and develop a compelling company narrative. Here is the very impressive result!

In today’s business world, it is not enough for scientist entrepreneurs and fundraising CEOs to simply have a great idea or product. In order to be successful, they must also have a clear and compelling narrative that effectively communicates the value of their work to potential investors and customers.

One of the key reasons that a strong narrative is so important is that it helps to differentiate a company or product from its competitors. In a crowded marketplace, it can be difficult to stand out and make a lasting impression on potential investors or customers. By having a clear and compelling story, a scientist entrepreneur or fundraising CEO can effectively communicate the unique value proposition of their product or idea, and why it is worth investing in.

Another important reason that a strong narrative is necessary is that it helps to build trust and credibility. When a scientist entrepreneur or fundraising CEO can clearly and effectively communicate the value of their work, it helps to instill confidence in potential investors and customers that the company or product is worth supporting. This is especially important when seeking funding or investment, as investors are more likely to put their money into a company or product that they believe in.

Finally, a strong narrative can also help to build a sense of community and engagement around a company or product. When people are able to connect with the story of a company or product, they are more likely to become invested in it and to want to support it. This can be especially beneficial for fundraising CEOs and scientist entrepreneurs, as it can help to generate interest and enthusiasm among potential investors and customers.

In conclusion, scientist entrepreneurs and fundraising CEOs need to get their story straight and develop a compelling narrative in order to effectively communicate the value of their work and stand out in a crowded marketplace. By doing so, they can build trust, credibility and a sense of community around their company or product and increase the chances of success.

Click on the podcast/class below to hear my take on the question above.

Hot Investor Mandate: Global Life Sciences Solutions Provider Seeks to Partner With and Invest in Early-Stage Companies Developing Diagnostics & Life Science Research Tools

2 Feb

A global leader in life sciences, diagnostics and applied chemical markets provides services, equipment, and support solutions to laboratories worldwide. The firm has an early stage partnership program that works with, and potentially invests in, early proof-of-concept to revenue stage companies that are a strategic fit to Agilent’s core products and services. Apart from financial investing, the firm provides strategic support to the companies with whom they partner. While the firm will partner globally, it has primarily partnered with US and European companies to this point.

The firm partners with early stage companies that provide game-changing tools, technologies and applications to advance the Life Science Research, Clinical Research and Diagnostic markets. Within these markets, the firm is especially interested in the fields of Bioproduction Instrumentation, Cell & Gene Therapy Tools, Cellular Engineering and Analysis, Genomics, Lab Data Analytics & Informatics, Molecular Diagnostics and Sample Preparation. The firm is currently not considering therapeutics or medical devices. The firm has partnered with companies early in proof of concept and up to revenue-generating companies.

The firm’s Early Stage Partnership program will only invest in companies that are a strategic fit, but operates as a financial investor, separating any strategic partnerships from the financial investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Investment Arm Branched Out of a Life Sciences Consulting Firm Seeks to Invest in Novel Therapeutics, Medtech, etc. Addressing Unmet Medical Need

2 Feb

A newly established venture capital firm headquartered in Western Europe is tied with a dedicated life sciences consulting firm with multiple offices throughout USA, Europe, and Asia. With the capability to leverage the experienced resources from the consulting firm, the firm is able to invest in and support in early-stage technologies with a derisked strategy. The firm has a pan-European focus and is sourcing globally within industry, start-up communities, and business accelerators, for high potential opportunities.

The firm is interested in proprietary, differentiated therapeutic products addressing high-unmet medical need and platform technologies supporting next-generation patient diagnosis, treatment and disease prevention. The interest areas also include genomics, AI, diagnostics, medical devices, rare diseases, next generation personalized medicine, and more. The firm is interested in early-stage opportunities – pre-clinical assets with a valid proof of concept, devices with a working prototype are all good fits in terms of stage of development.

The firm will look at each opportunity carefully, and is most interested in those with business potential with a 3-5 year runway to strategic partnerships, acquisition by large life science companies or an IPO. The firm will prefer to lead investments and will take a very active role in their portfolio companies, often being involved in the operations of these companies to support their growth and enabling research that generates important, proof-of-concept data.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based Investment Firm With Ties to Major Insurance Provider Invests Up to $20M in Digital Health, Healthcare Services, and More

2 Feb

An investment firm based in the US looks to invest in healthcare companies of strategic interest to a major healthcare insurance company that the firm has ties with, while seeking strong financial returns. With the fund, the firm is looking to make investments ranging from $1 – $20 million over the lifetime of the investment in stages ranging anywhere from seed to buyout. The firm is actively reviewing new opportunities and will consider companies located around the globe that are commercializing in the US or plan to in the near future. The firm also manages other funds that seek to invest in food and agriculture companies and insurtech companies, respectively.

Within the healthcare space, the firm looks to invest across Healthcare IT, Services, Diagnostics, and Devices, and agnostic towards types of technologies and indication areas the technologies address.

The firm is looking for companies with experienced management teams and prefers working with complete teams although they also have experience and are willing to work with incomplete management teams as well. The firm is looking for privately held companies and prefers to lead in rounds but can co-invest in certain circumstances. The firm generally looks to take a board seat following an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Biotech Company in USA Seeks Pre-Clinical Therapeutic Assets in Immuno-Oncology and Autoimmune Diseases for Potential In-Licensing or Investment

2 Feb

A biotech company based in the USA has an active pipeline of therapeutic assets in immuno-oncology and autoimmune diseases. The firm has been seeking novel therapeutics opportunities that are synergistic with the firm’s existing pipeline for potential licensing, investment, and other partnership opportunities. The firm is most interested in opportunities based in US and Europe.

The firm is seeking therapeutic opportunities for potential licensing, investment, and other win-win partnership opportunities. The firm is open to novel targets and modalities; in terms of indication/disease area, the firm is only considering immuno-oncology and autoimmune diseases at this time. In terms of stage of development, the firm will primarily consider pre-clinical stage assets.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Digital RESI March – Super Early Bird Ends Tomorrow! Take The Test Below and See What Ticket You Should Buy

26 Jan

By Greg Mannix, Vice President International Business Development, General Manager Europe, LSN

One positive lesson from the past 3 years is that digital partnering conferences can be extremely valuable and cost-effective. As much as we all value the chance to go back to in-person events, Digital RESI March 14-16 is a terrific opportunity to meet with 300+ early-stage investors and licensing partners at a fraction of the overall cost of attending an in-person event.

Life Science Nation (LSN) is committed to continuing to offer digital RESI events together with our signature in-person RESI conferences. Digital RESI March will again offer insightful investor and workshop panels, plus the chance to pitch live to a panel of domain-specific investors in the Innovator’s Pitch Challenge (IPC). Companies that compete in the IPC get great visibility, make valuable connections, and have found they are more successful in getting meetings with investors and licensing partners. IPC applications are now being accepted.

NEW! Global Partnering Campaign & Roadshow Preparation Entrepreneurial Education Series

2023 is an important year for LSN’s Entrepreneurial Education programs. We have devised 16+ focused and very practical 1-hour classes that address genuine issues facing startups. At Digital RESI March we will be offering an educational track for the first time, consisting of 6 focused classes over 3 days and covering topics like:

  • It All Starts with The Story
  • First-Time CEOs: Avoiding Pitfalls
  • Tagline & Elevator Pitch
  • Executive Summary & Tear Sheet
  • Pitch Deck & The 10 Myths of Fundraising
  • Strategies for Successful Partnering

Take The Test and See What Ticket You Should Buy

RESI March with Partnering

Have you already launched your global Partnering Campaign and attended partnering events? Are you into actively seeking capital investors and licensing partners? Do you have your story straight and your branding and messaging in place? Do you have a global target list of partners and are you using a CRM to organize and manage the interactions with that list? LSN suggests a full 3-day partnering conference registration. ($1,195)

Apply for the Innovators Pitch Challenge

Are you ready or have you participated in the Innovator’s Pitch Challenge (IPC)? This will get you feedback from qualified investors and licensing partner judges and help you with feedback and commentary on your pitch presentation. Click here to apply to the IPC. This package will include a full day 3-day registration plus the IPC package. ($1,795)

On the Edge and Need to Learn More as an Early-Stage Startup Looking for strategic Partners

Just getting started and trying to learn the ropes? Need to learn from the investor and licensing partner panels precisely what partners look for. Seeing is believing. Watch other startup CEOs participate and pitch their startups to global partners. Take advantage of LSN’s Global Partnering Campaign and Roadshow Preparation classes. This low-cost audience pass will give you access to all the RESI content through panels and classes over the three days. The audience pass is aimed at helping startups who are not quite ready for their global partnering campaign see how other colleagues have made the leap and are actively executing partnering roadshows. You can virtually attend our investor panels and entrepreneurial educational classes. ($295)

Super Early Bird ends tomorrow for Digital RESI March so be sure to register here today to save $300!

Register-now-button-new

RESI March 2023 Digital Copy (FULL Banner Size)